Oral absorption of clarithromycin in acute illness and during convalescence in patients with community-acquired pneumonia

Chest

Volumn 117, Issue 4, 2000, Pages 1090-1093

  Offman, Elliot ^a   Varin, Frances ^a   Nolan, Tom ^a   Bayliff, Charlie D ^a   Bombassaro, Anne Marie ^a   McCormack, Dave G ^a  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Acute illness; Clarithromycin; Community acquired pneumonia; Pharmacokinetics

Indexed keywords

CLARITHROMYCIN;

ACUTE DISEASE; ADULT; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONVALESCENCE; DRUG ABSORPTION; FEMALE; HUMAN; MALE; PNEUMONIA; PRIORITY JOURNAL;

EID: 0034007952     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.117.4.1090     Document Type: Article

References (22)

1. 1 Jellett LB, Heazelwood VJ. Pharmacokinetics in acute illness. Med J Aust 1990; 153:534-541
2. 2 Louie TJ. Intravenous to oral step-down antibiotic therapy: another cost-effective strategy in an era of shrinking health care dollars. Can J Infect Dis 1994; 5:45C-50C
3. 3 Pittet D, Tarara D, Wenzel R. Nosocomial bloodstream infection in critically ill patients: excess length of stay, extra costs, and attributable mortality. JAMA 1994; 271:1598-1601
4. 4 Biaxin product monograph. Compendium of pharmaceuticals and specialties. 34th ed. Ottawa, Ontario: Canadian Pharmacists Association; 1999
5. 5 Niederman MS. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society Medical Section of the American Lung Association. Am Rev Respir Dis 1993; 148:1418-1426
6. 6 Bartlett JG. Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America. Clin Infect Dis 1998; 26:811-838
7. 7 Gotfried MH, Killian A, Servi R, et al. Oral clarithromycin versus intravenous erythromycin for the treatment of community-acquired pneumonia in hospitalized patients. Third International Conference on the Macrolides, Azalides and Streptogramins [abstract]. (poster) 1996
8. 8 Skupien D, Margulis A, Kaczander N, et al. Randomized comparative trial of the safety, efficacy and cost of intravenous cefuroxime plus erythromycin vs. intravenous cefuroxime plus oral clarithromycin in the therapy of community-acquired pneumonia. Third International Conference on the Macrolides, Azalides and Streptogramins [abstract]. (poster) 1996
9. 9 Horn J, Hansten P Drug interactions: analysis and management. Vancouver, WA: Applied Therapeutics, 1997
10. 10 Fine MJ, Auble TE, Yealy SM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243-250
11. 11 Farr BM. Prognosis and decisions in pneumonia. N Engl J Med 1997; 336:288-289
12. 12 Chu SY, Senello LT, Sonders RC. Simultaneous determination of clarithromycin and 14(R)-hydroxyclarithromycin in plasma and urine using high-performance liquid chromatography with electrochemical detection. J Chromatogr 1991; 571:199-208
13. 13 Blackwelder WC. "Proving the null hypothesis" in clinical trials. Control Clin Trials 1982; 3:345-353
14. 14 Ware JH, Antman E. Equivalence trials. N Engl J Med 1997; 337:1159-1161
15. 15 Young MJ, Bresnitz E, Strom B. Sample size nomograms for interpreting negative clinical studies. Ann Intern Med 1983; 99:248-251
16. 16 Nightingale C. The pharmacokinetic profile of clarithromycin. Infect Med 1997; 14(SupplC):8-16
17. 17 Langtry HD, Brogden R. Clarithromycin: a review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients. Drugs 1997; 53:973-1004
18. 18 Chu SY, Wilson D, Guay D, et al. Clarithromycin pharmacokinetics in healthy young and elderly volunteers. J Clin Pharmacol 1992; 32:1045-1049
19. 19 Glantz SA. Primer of biostatistics. 1992
20. 20 Dean S, Harding L, Wise R, et al. Absorption and excretion of cephalexin in health and acute illness. Eur J Clin Pharmacol 1979; 16:73-74
21. 21 Guay DR, Awni W, Peterson P, et al. Pharmacokinetics of ciprofloxacin in acutely ill and convalescent elderly patients. Am J Med 1987; 82:124-129
22. 22 Davey PG. The pharmacokinetics of clarithromycin and its 14-OH metabolite. J Hosp Infect 1991; 19(SupplA):29-37